Wednesday, July 8, 2026

Drug profile · INN

sonrotoclax

sonrotoclax (BEQALZI) is an FDA-listed pharmaceutical active ingredient. Associated with BEONE MEDICINES AUS PTY LTD. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 6
News articles 0
Drug details — sonrotoclax
US status
approved
Class
Route
ORAL
Patents
0
Programs
6
Data quality
0.89

Quick answer

sonrotoclax (BEQALZI) is an FDA-listed pharmaceutical active ingredient. Associated with BEONE MEDICINES AUS PTY LTD. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN sonrotoclax
Brand BEQALZI
Route ORAL
Formulation TABLET

Approval history

Authority Status Date
FDA approved

Pipeline programs

  1. Sonrotoclax Phase 3 · BEONE MEDICINES AUS · CLL
  2. Sonrotoclax Phase 3 · BEONE MEDICINES AUS · Chronic Lymphocytic Leukemia
  3. Sonrotoclax Phase 3 · BEONE MEDICINES AUS · Mantle Cell Lymphoma
  4. Sonrotoclax Phase 2 · BEONE MEDICINES AUS · Relapsed/Refractory Multiple Myeloma
  5. Sonrotoclax Phase 2 · BEONE MEDICINES AUS · Waldenstrom Macroglobulinemia
  6. Sonrotoclax Phase 1 · BEONE MEDICINES AUS · Mature B-Cell Malignancies

Frequently asked questions

What is sonrotoclax?

sonrotoclax (BEQALZI) is an FDA-listed pharmaceutical active ingredient. Associated with BEONE MEDICINES AUS PTY LTD. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for sonrotoclax?

BEQALZI is a marketed brand name for sonrotoclax. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of sonrotoclax?

sonrotoclax has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.